A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526)

We report the primary endpoint of the phase 2 NRG/RTOG 0526 trial of salvage low dose rate prostate brachytherapy for locally recurrent prostate cancer following prior external beam radiotherapy (EBRT). Eligible patients initially presented with favorable or intermediate risk prostate cancer. At a median follow up of 54 months, 12 of 92 analyzable patients (14%) had late grade 3 gastrointestinal or genitourinary adverse events, which did not exceed the previously set threshold for unacceptable toxicity.

Source: International Journal of Radiation Oncology * Biology * Physics - October 9, 2018 Category: Radiology Authors: Juanita M. Crook, Peixin Zhang, Thomas M. Pisansky, Edouard J. Trabulsi, Mahul B. Amin, William Bice, Gerard Morton, Nadeem Pervez, Eric Vigneault, Charles Catton, Jeff Michalski, Mack Roach, David Beyer, Ashesh Jani, Eric Horwitz, Viroon Donavanik, Howar Tags: Clinical Investigation Source Type: research